Overview

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

A Randomized, Double-Blind, Multicenter, phase III Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan (BR-A-657·K) 30mg Compared to Placebo in Patients with Mild to Moderate Essential Hypertension

Phase:

Phase 3

Details

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Collaborators:

Asan Medical Center
Bucheon St. Mary's Hospital
Daegu Fatima Hospital
Dong-A University
Ewha Womans University Mokdong Hospital
Gangnam Severance Hospital
Hallym University Medical Center
Hanyang University
Jeju National University Hospital
Kangbuk Samsung Hospital
Konyang University Hospital
Korea University Anam Hospital
National Health Insurance Service Ilsan Hospital
Sejong General Hospital
Severance Hospital
Soon Chun Hyang University
Ulsan University Hospital

Treatments:

Antihypertensive Agents
Valsartan